Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
Khanani AM, Dugel PU, Haller JA, Wagner AL, Lescrauwaet B, Schmidt R, Bennison C. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US. J Comp Eff Res. 2020 03; 9(4):287-305.